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In this month’s issue, Patsch and colleagues
(1) offer ample
food for thought for anyone interested inmarrow adipocytes,
the enigmatic endosteal fat cells whose developmental origins,
function, and impact on bone mass are currently subjects of
active investigation.(2) Marrow fat is often associated with low
bonemass, as in anorexia nervosa, aging, and osteoporosis, but
is also present in normal bone in complex age‐, sex‐, and site‐
speciﬁc patterns.(3–5) Although marrow adipocytes were
historically assumed to be neutral, quiescent space ﬁllers,(6)
recent studies have demonstrated that marrow adipose tissue
has a role in systemic energy metabolism(7,8) and that bone
marrow fat mass and bone mass are inversely correlated even
within normal subjects.(9,10) Marrow fat is now understood as a
metabolically active depot that can be mobilized in starvation
and that exerts potential beneﬁcial as well as deleterious
effects on skeletal and overall metabolism. However, many
questions remain about exactly howmarrow fat might increase
fracture risk, and how this risk varies with age, sex, and
comorbidities.
Patsch and colleagues(1) tackle two key outstanding questions
about marrow fat: whether the composition of marrow fat, as
opposed to the quantity, is related to fracture risk; and whether
there is an interaction betweenmarrow fat, diabetes, and skeletal
fragility. To address these questions, the authors measured
vertebral bone marrow adiposity via magnetic resonance
imaging (MRI), areal bone mineral density (aBMD) by dual‐
energy X‐ray absorptiometry (DXA), and volumetric BMD (vBMD)
by quantitative computed tomography (QCT) in the lumbar spine
(L1–L3) in postmenopausal women with and without prior
fracture history and with or without type 2 diabetes. Marrow fat
quantiﬁcation included both the total lipid and the proportions
of saturated, unsaturated, and residual lipid, differentiated by the
presence or absence of double bonds.
Overall, the results corroborate patterns seen in previous
studies: aBMD at the hip and spine was highest in women with
type 2 diabetes but no fracture, and lowest in nondiabetic
womenwith prior fracture, whereas vBMD of the spinewas lower
in women with fracture versus women without fracture, both
within controls and within diabetics. Interestingly, there were no
differences in total marrow fat content among groups, regardless
of diabetes or fracture status, in contrast to at least one recent
study that found higher vertebral marrow fat in subjects with
prevalent vertebral fractures.(11) However, both diabetes and
fracture history were correlated with differences in marrow fat
composition. As shown in Table 2 in Patsch and colleagues,(1) the
degree of unsaturation was lower in individuals with both
diabetes and fractures (DMFx) compared to controls without
fracture (Co) and diabetics without fracture (DM), and the degree
of saturation was higher in DM and DMFx versus Co. In other
words, people with diabetes hadmore saturatedmarrow fat, and
people with diabetes and history of fracture had less unsaturated
marrow fat, compared to controls without fracture. However,
while type 2 diabetes and fracture were each related to bone
marrow adiposity, these correlations were independent of one
another. After adjustment for age, ethnicity, and aBMD, therewas
no interaction between type 2 diabetes, fracture, and total
marrow fat, nor any of the subsets of marrow fat—saturated,
unsaturated, or residual. Patsch and colleagues’(1) interpretation
was that diabetes and fracture have additive, negative effects on
bone marrow composition. Given the cross‐sectional study
design, further studies will be needed to validate the direction of
causality.
These ﬁndings challenge our current understanding of the
relationship between marrow fat and bone in several key ways,
and generate a host of intriguing questions for future work. First
and foremost is the provocative conclusion that it is the
composition, rather than the amount, of marrow fat that is
correlated with fracture history and diabetes. This ﬁnding
corroborates previous studies that found lower unsaturation in
osteoporosis and in diabetes, both of which involve elevated
fracture risk,(5,12) but contrasts with studies that have shown an
inverse relationship between the quantity of marrow fat and
BMD or bone mass.(3,9,10,13) Additionally, this ﬁnding raises the
issue of causality—does marrow fat become less unsaturated
before a fracture, or afterward? Does altered metabolism in
diabetes change marrow lipid composition and thereby increase
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skeletal fragility? As Patsch and colleagues(1) note, the ﬁnding
that a high ratio of saturated to unsaturated lipid confers more
fracture risk than the amount of lipid alone may help to explain
why people with diabetes have more fractures than would be
expected based on their BMD alone.(14) However, the question
remains unanswered as to exactly how marrow fat, and in
particular lower unsaturated marrow fat, is deleterious to bone.
As has been widely noted, endosteal adipocytes and osteoblasts
are derived from the same pool of progenitor cells, such that an
increase in adipocyte differentiation might lead to a decrease in
osteoblast differentiation,(15) and adipocyte accumulation also
seems to impair osteoblast function.(16) The study by Patsch and
colleagues(1) challenges us to understand whether less unsatu-
rated lipid and/or more saturated lipid are somehow themselves
deleterious to bone, or whether these composition changes are
indicators of other underlying mechanisms that increase skeletal
fragility. As the authors note, there is a relationship between
dietary fat intake and fracture, with high dietary intake of
polyunsaturated fats being associated with lower hip fracture
risk.(17) It remains to be seen whether this dietary effect is
mediated by marrow fat composition.
Second, the ﬁnding that fracture and diabetes are each
independently associated with changes in marrow fat composi-
tion raises the possibility that marrow adiposity in general, and
the ratio of unsaturation to saturation in particular, may arise via
more than one mechanism. The question of what mechanism(s)
trigger abnormal marrow fat formation is obviously of great
clinical interest, but an even more interesting question is what
the “normal” quantity and composition (saturated versus
unsaturated) of marrow fat is across a person’s lifetime.
Progressively higher bone marrow adiposity has long been
noted as normal component of skeletal maturation (eg,
Neumann, 1882; discussed in Tavassoli(18)). Through childhood,
the predominantly hematopoietic marrow of the infant is
replaced by fatty marrow in a distal‐to‐proximal gradient, such
that the limbs of the adult skeleton contain predominantly
yellow marrow.(4) Thus, marrow adiposity is not necessarily
deleterious to bone, and criteria for determining when it is
deleterious remain to be delineated. In fact, the most rapid
increase inmarrow adiposity in humans occurs at puberty, a time
of rapid skeletal acquisition, an important reminder that
concurrent increases in marrow fat and bone mass are not
always mutually exclusive.(3) A similar phenomenon is seen in
inbred mice, in which marrow adiposity and bone mass are
inversely correlated in the C57Bl/6J strain,(19) but positively
correlated in the C3H strain.(20)
Animal models also provide some key insights into the
mechanism(s) of abnormally highmarrow adiposity. In the ob/ob
(obese) leptin‐deﬁcient mouse, high marrow fat occurs in
association with hypoleptinemia and is reduced by leptin
treatment.(21) Hypoleptinemia is also seen along with high
marrow fat in humans with anorexia nervosa,(3) but is less
characteristic of other skeletal pathologies of high marrow
adiposity, such as osteoporosis, diabetes, or unloading.(22–25)
Other hormonal states linked to marrow fat in humans and/or in
animal models include high preadipocyte factor 1 (Pref‐1),
particularly in anorexia;(26) peroxisome proliferator‐activated
receptor g (PPARg) agonism;(27) low estrogen, seen in anorexia
and osteoporosis;(28) low osteocalcin;(29) and disruption of the
growth hormone–insulin‐like growth factor–1 (GH‐IGF‐1) axis.(30)
Furthermore, the recent complementary ﬁndings that marrow
adipocytes are negative regulators of hematopoiesis andmarrow
osteoblasts are positive regulators of hematopoiesis(31,32)
suggest the possibility that highmarrow fat could be a byproduct
of downregulated hematopoiesis, and thus stimulating blood
cell formation might consequently reduce marrow adiposity, but
whether such a reversal would also increase bone mass is an
open question.
Perhaps the ultimate challenge raised by Patsch and
colleagues(1) will be to determine whether the total quantity
of marrow fat and/or the ratio of saturated to unsaturated fat
can be manipulated environmentally (eg, through diet) or
pharmacologically (eg, by leptin treatment), and whether such
manipulations improve bone mass or decrease fracture risk.
For example, high marrow adiposity is ameliorated by weight
recovery in anorexia,(20,33) and high saturation of bone marrow
fat might be too. The work of Krings and colleagues(7) and
Lecka‐Czernik(8) suggests that gene expression of bone
marrow adipocytes changes over a person’s lifetime, becoming
less like brown fat and more like white fat with aging and
diabetes, and it will be extremely interesting to see whether
those changes in gene expression are linked to marrow fat
composition changes, and whether marrow fat gene expres-
sion might also be moderated by environmental or pharmaco-
logical inﬂuences.
To summarize, current evidence indicates that bone marrow
fat is a dynamic tissue that is distinct from white fat and brown
fat, and that perhaps has markedly different effects on bone
across the life course and in normal versus disease states. The
work of Patsch and colleagues(1) emphasizes that the character-
istics of marrow fat—speciﬁcally the proportion of saturated
versus unsaturated lipid—may be clinically relevant regardless of
the absolute quantity of fat, and that such composition changes
are independently associated with prior fracture and with
diabetes. Future studies will undoubtedly extend these obser-
vations to other ages, to males, and to a broader array of disease
states characterized by high marrow fat. However, it must be
acknowledged that magnetic resonance imaging (MRI) remains
an expensive imaging modality for everyday use, and the results
of this study require replication and validation before marrow fat
composition can be used to inform clinical decisions. Ultimately,
marrow fat composition has the potential to be a particularly
useful adjunct to DXA in populations in which BMD is less
predictive of fracture risk, such as patients with diabetes. Further
work should focus not only on understanding the function of
marrow fat, but also on developing more cost‐effective ways to
quantify it.
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